Abstract
The molecular classification of Perou and Sørlie breast tumors has to streamline, systematize and make effective use of targeted therapies against specific molecular subtypes, including breast HER2 positive. Trastuzumab and lapatinib are currently the two therapies targeting HER2, which have demonstrated their effectiveness in clinical practice. This literature review aims to make the data points on pertinent and useful data for physicians in daily.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Brain Neoplasms / prevention & control
-
Brain Neoplasms / secondary
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics
-
Female
-
Genes, erbB-2
-
Heart / drug effects
-
Humans
-
Lapatinib
-
Molecular Targeted Therapy / methods*
-
Quinazolines / adverse effects
-
Quinazolines / therapeutic use*
-
Receptor, ErbB-2 / antagonists & inhibitors*
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Antineoplastic Agents, Hormonal
-
Quinazolines
-
Lapatinib
-
Receptor, ErbB-2
-
Trastuzumab